Nan Mou

Shanghai Genon Biological Products (China) — China

Medicine · Health Sciences

8h-index243citations23works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(19), Virus-based gene therapy research(6), Viral Infectious Diseases and Gene Expression in Insects(6), Integrated Circuits and Semiconductor Failure Analysis(3), Cancer Immunotherapy and Biomarkers(2)

Publications23 total

Efficacy and side effects of <scp>anti‐CD19 CAR</scp> T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma
Cancer Medicine·2024· 2 citedOpen Access
Cyclic RGD-Functionalized pH/ROS Dual-Responsive Nanoparticle for Targeted Breast Cancer Therapy
Pharmaceutics·2023· 14 citedOpen Access
Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors
Frontiers in Immunology·2023· 15 citedOpen Access
Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL
Annals of Hematology·2023· 2 cited
Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant
Cell Transplantation·2023· 3 citedOpen Access
To compare the efficacy and safety of radiotherapy before and after anti-CD19-CAR T-cell therapy in patients withrelapsed/refractory DLBCL
Research Square (Research Square)·2022Open Access
The expression and significance of efferocytosis and immune checkpoint related molecules in pancancer samples and the correlation of their expression with anticancer drug sensitivity
Frontiers in Pharmacology·2022· 18 citedOpen Access
Efficacy and safety related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL
Research Square (Research Square)·2022Open Access
Luteolin attenuates the pathogenesis of Staphylococcus aureus by interfering with the agr system
Microbial Pathogenesis·2022· 33 cited
Association Analysis of Persistent Cytopenia With Efficacy and Side Effects of Anti-CD19 CAR T Therapy in Relapsed/refractory Diffuse Large B-Cell Lymphoma Patients.
2022Open Access
Efficacy and safety of humanized CD19 CAR‑T as a salvage therapy for recurrent CNSL of B‑ALL following murine CD19 CAR‑T cell therapy
Oncology Letters·2021· 7 citedOpen Access
[Activity comparison of humanized CD19 CAR-T cells with murine CD19 CAR-T on Nalm-6 cells and xenograft tumor model].
PubMed·2021· 1 cited
Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk
Frontiers in Oncology·2021· 13 citedOpen Access
Abstract 1499: Targeting Ras mutation with TCR therapy
Cancer Research·2021· 1 cited
[Overexpression of NKG2D-CD3ζ in NY-ESO-1 TCR-T cells enhanced cytotoxicity to acute myeloid leukemia cells <i>in vitro</i>].
PubMed·2020Open Access
Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant
Frontiers in Oncology·2020· 57 citedOpen Access
Humanized anti‐CD19 chimeric antigen receptor‐T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection
Hematological Oncology·2020· 26 citedOpen Access
Author response for "Humanized anti‐CD19 CAR‐T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved HBV infection"
2020
Author response for "Humanized anti‐CD19 CAR‐T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved HBV infection"
2020Open Access
Efficacy and safety of humanized anti‐CD19‐CAR‐T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia
British Journal of Haematology·2020· 50 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Qi Deng(14), Rui Cui(10), Qing Li(10), Zhenxing Yang(8), Yanyu Jiang(8), Juan Mu(8), Meijing Liu(7), Cuicui Lyu(7), Jia Wang(7), Xuxiang Liu(4), Xin Li(4), Jijun Yuan(4), Jia Wang(3), Fengjun Sun(3), Qi Deng(3), Yuan Qian(2), Qianmei Wang(2), Lanfang Li(2), Bangbi Weng(2), Yili Jiang(2)